By Dean Gittleman
The issue of clinical trial costs, both in terms of money and time, is big, complicated, and not at all new. In this article, I will not attempt to address or solve all of the problems that contribute to these high costs, but I will highlight some continuing root causes that I believe persist needlessly.
I’ll focus on execution, leaving issues surrounding study design complexity and lack of discipline to another day. Tradition and inertia are poor excuses to continue perpetuating some of these practices — conducting 21st-century trials with a 20th-century mindset is bound to fail.